NextCell Pharma changes ticker to NXTCL

NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL.

Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management has
decided to change the ticker to NXTCL. The new abbreviation might also be used in general market communications
and company branding.

The new ticker will become effective as per 2018-02-07, the company name and ISIN-code (SE0009723125) will
remain the same.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse
Regulation. The information was provided by the below contact person for publication on January 31th, 2018.

För mer information om NextCell Pharma AB, vänligen kontakta:

Mathias Svahn, VD

Leo Groenewegen, CFO

Telefon: 08-735 5595

E-post: info@nextcellpharma.com

www.nextcellpharma.com

About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell

Pharma AB develops ProTrans™, a drug candidate consisting of stem cells for the primary treatment of autoimmuneand inflammatory diseases as well as for use in kidney transplants. ProTrans™ consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.

Subscribe

Documents & Links